AKEBIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
AKEBIA THERAPEUTICS, INC. (AKBA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 5.75 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 878.80K shares, a 9.58% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 4.87M shares, a 26.43% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 272.30K shares, a 89.10% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 537.76K shares, a 230.73% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.46M shares, a 2.25% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 5.34M shares, a 24.72% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.28M shares.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 1.33M shares, a 5.96% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 878.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 5.75M shares 10-Q · filed 2026-08-05 | 6.02M shares derived: sum of 3 quarters · filed 2026-08-05 | 6.56M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 4.87M shares 10-Q · filed 2026-05-07 | 5.14M shares derived: sum of 2 quarters · filed 2026-05-07 | 5.68M shares derived: sum of 3 quarters · filed 2026-05-07 | 6.48M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 272.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 810.06K shares derived: sum of 2 quarters · filed 2026-02-26 | 1.61M shares derived: sum of 3 quarters · filed 2026-02-26 | 5.46M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 537.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 1.34M shares derived: sum of 2 quarters · filed 2025-11-10 | 5.19M shares 10-Q · filed 2025-11-10 | 5.34M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 802.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 4.65M shares 10-Q · filed 2025-08-07 | 4.80M shares derived: sum of 3 quarters · filed 2025-08-07 | 4.96M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 3.85M shares 10-Q · filed 2025-05-08 | 4.00M shares derived: sum of 2 quarters · filed 2025-05-08 | 4.16M shares derived: sum of 3 quarters · filed 2025-05-08 | 5.11M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 144.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 306.60K shares derived: sum of 2 quarters · filed 2025-03-13 | 1.26M shares derived: sum of 3 quarters · filed 2025-03-13 | 5.34M shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 162.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.11M shares derived: sum of 2 quarters · filed 2024-11-07 | 5.20M shares 10-Q · filed 2024-11-07 | 5.34M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 949.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 5.04M shares 10-Q · filed 2024-08-08 | 5.18M shares derived: sum of 3 quarters · filed 2024-08-08 | 5.81M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 4.09M shares 10-Q · filed 2024-05-09 | 4.23M shares derived: sum of 2 quarters · filed 2024-05-09 | 4.86M shares derived: sum of 3 quarters · filed 2024-05-09 | |
| 2023-12-31 | 141.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 770.00K shares derived: sum of 2 quarters · filed 2024-03-14 | 4.28M shares 10-K · filed 2024-03-14 | |
| 2023-09-30 | 629.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 4.14M shares 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | 3.51M shares 10-Q · filed 2023-08-28 | |||
| 2017-12-31 | 1.33M shares 10-K · filed 2018-03-12 | |||
| 2016-12-31 | 1.42M shares 10-K · filed 2017-03-06 | |||
| 2015-12-31 | 992.05K shares 10-K · filed 2016-03-14 | |||
| 2014-12-31 | 514.81K shares 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |